CVRx, Inc. (CVRX), a cardiovascular medical device company, has initiated BENEFIT-HF, a clinical trial to evaluate the impact of Barostim, an FDA-approved implantable device, in an expanded heart failure population.
Barostim is an implantable device that delivers electrical signals to baroreceptors located on the carotid artery, increasing baroreflex signalling, rebalancing the autonomic nervous system, and improving heart failure symptoms.
For comments and feedback contact: editorial@rttnews.com
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.